EGFR and breast carcinoma: A shorter time period was used for estimating the doses from 111In-DTPA-human epidermal growth factor (111In-DTPA-hEGF) in 15 patients with EGFR positive breast cancer using whole body planar images acquired at 1, 4–6, 24 and 72 h p.i., since radiopeptides are eliminated more rapidly than mAbs (Vallis et al. 2014).